Two-, three-, and four-drug antiretroviral combinations in either simultaneous or sequential regimens were evaluated for their ability to suppress human immunodeficiency virus (HIV) type 1 replication in vitro. Zidovudine, lamivudine, saquinavir, and nevirapine were used at IC 90 s, IC 99 s, or IC §99 s in a CD4-positive human lymphoblastoid cell line (H9 cells) acutely infected with HIV-1. In sequential regimens, drugs were added at weekly intervals. In simultaneous regimens, all drugs were added on day 0. Increasing the number of drugs in a combination regimen both increased the degree of viral inhibition and delayed the time of breakthrough viral replication. Simultaneous regimens provided more profound and earlier viral inhibition than did sequential regimens. However, sequential addition provided relatively more durable viral inhibition than did simultaneous regimens when drug concentrations were low. The relative effectiveness of different HIV-1 therapeutic strategies depends on both the numbers and concentrations of the drugs used.
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Two-, three-, and four-drug antiretroviral combinations in either simultaneous or sequential regimens were evaluated for their ability to suppress human immunodeficiency virus (HIV) type 1 replication in vitro. Zidovudine, lamivudine, saquinavir, and nevirapine were used at IC 90 s, IC 99 s, or IC §99 s in a CD4-positive human lymphoblastoid cell line (H9 cells) acutely infected with HIV-1. In sequential regimens, drugs were added at weekly intervals. In simultaneous regimens, all drugs were added on day 0. Increasing the number of drugs in a combination regimen both increased the degree of viral inhibition and delayed the time of breakthrough viral replication. Simultaneous regimens provided more profound and earlier viral inhibition than did sequential regimens. However, sequential addition provided relatively more durable viral inhibition than did simultaneous regimens when drug concentrations were low. The relative effectiveness of different HIV-1 therapeutic strategies depends on both the numbers and concentrations of the drugs used.
Monotherapy of human immunodeficiency virus (HIV) type
Materials and Methods 1 with currently available antiretroviral agents has achieved quentially at weekly intervals for their ability to suppress HIVwere suspended in 2 mL of R20 medium in 24-well tissue culture plates in triplicate. Simultaneously, drugs and a virus inoculum of 1 replication in acutely infected H9 cells.
either 4000 or 40,000 TCID 50 (MOI Å 0.005 or 0.05, respectively) were added to the wells, without a subsequent wash. Wells containing medium plus virus only were also maintained in parallel 3-drug combinations at IC 99 ) developed phenotypic resistance to lamivudine. Lamivudine IC 50 s for the breakthrough viruses were Ç1.5 log higher than those for untreated control virus.
Results
Viruses that showed breakthrough replication against 4-drug In all experiments, increasing the number of drugs in a comcombinations, in either simultaneous or sequential regimens, bination regimen both increased the degree of viral inhibition were still susceptible to all of the drugs used. and delayed the time of breakthrough viral replication.
In experiments with low MOI (0.005) and IC §99 (figure 2E, In experiments using drugs at IC 90 concentrations (figure F), all but the 2-drug sequential regimens were able to eliminate 2A, B), neither sequential nor simultaneous 2-drug combination HIV-1 replication for up to 140 days in culture. However, when regimens were effective in inhibiting HIV-1 replication. In 3-infections with higher virus input (MOI of 0.05) were treated drug combinations, the sequential regimen provided minimal with the same concentrations of drugs, 2-and 3-drug sequential but more durable suppression of HIV-1 replication than did regimens failed to durably suppress viral replication, whereas the simultaneous regimen. In 4-drug combinations, the simulta-4-drug sequential and all simultaneous regimens were able to neous regimen was able to suppress viral replication to undecompletely suppress viral replication ( figure 2G, H) . tectable levels by day 31, but breakthrough replication develIn all of the experimental conditions in which drug combinaoped soon after. In contrast, the sequential 4-drug regimen tions eliminated detectable p24 antigen, cultures were mainsuppressed viral replication up to day 100, although the degree tained in the absence of drugs for an additional 14 days. They of initial suppression was less than that in the simultaneous remained negative for p24 antigen for the duration of the experregimen. These observations were reproducible in at least 2 iments. experiments (data not shown).
There was no evidence of drug toxicity as measured by When higher concentrations (IC 99 ) of drugs were used cell viability and proliferation of treated, but uninfected, cells maintained in parallel. 06-24-97 13:57:36 jinfal UC: J Infect resulted in greater suppression than did 2-drug combinations. InWe were able to eliminate detectable HIV-1 replication from cultures by use of several combination regimens. All of the effeccreasing the number of drugs in a combination also provided more durable suppression of viral replication. These findings support tive drug concentrations in this study can be achieved clinically. However, our studies do not necessarily indicate that HIV-1 infecprevious in vitro studies [1, 6, 10] . Recent clinical trials have also shown that 2-drug combination regimens may be superior to single tion can be eradicated with these regimens. Virus inocula in our experiments, ranging from 4000 to 40,000 TCID 50 , were orders drugs and that 3-drug regimens provide greater and more sustained increases in CD4 cell counts and decreases in virus load than do of magnitude lower than plasma virus levels and turnover observed in vivo [15] . In addition, there are no isolated drug sanctu-2-drug regimens [11] .
Simultaneous combinations provided more rapid and complete aries in our in vitro acute infection model. Moreover, we did not evaluate our ''virus-free'' cells for the presence of latent genomes suppression of HIV-1 replication than did regimens using sequential administration of drugs. When relatively high concentrations by sensitive molecular assays, although they failed to produce p24 antigen even in the absence of drug. (IC 99 ) of drugs were used, 4-drug combinations in either simultaneous or sequential regimens were effective in eliminating HIVIn summary, our results suggest that simultaneous antiretroviral regimens are most advantageous when used at high effective 1 replication for up to 110 days in culture ( figure 2C, D) . In this circumstance, simultaneous regimens eliminated viral replication concentrations relative to virus burden and provide more rapid and more profound inhibition than do sequential regimens. Howmore rapidly than did sequential regimens. Simultaneous combinations of 3 drugs also caused earlier and more profound initial ever, when drug concentrations are low relative to virus burden, certain sequential regimens, in which new drugs are added at suppression than did sequential 3-drug regimens, even though neither sequential nor simultaneous 3-drug regimens could comfrequent intervals and before emergence of resistant virus, may be useful. Only by carefully controlled clinical trials can the in pletely eliminate viral replication.
Although sequential addition of drugs might reduce acute vivo validity of these hypotheses be established. toxicity and allow easier identification of those drugs causing toxicity, the addition of individual drugs to a regimen over
